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Arteriogenesis, the transformation of preexisting collaterals
into mature collaterals, is influenced by multiple factors.
More than 15 growth factors that can stimulate collateral
growth or angiogenesis have been identified [1,2]. Because
vascular endothelial growth factor (VEGF) is believed to be
involved in angiogensis in vivo, there are many therapeutic
studies on the use of VEGF as a therapeutic angiogenesis
agent in severe coronary disease patients who cannot undergo
standard revascularization [3]. Transforming growth factor `
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(TGF-`1) is also involved in angiogenesis, which is blocked
by TGF-`1 antibodies [4]. In addition, TGF-`1 signaling may
regulate VEGF expression in cardiac myocytes [5].
Hypoxia stimulates VEGF release [6]. Therefore, the
severity of coronary artery stenosis, a cause of hypoxia, is
also a critical determining factor in collateral channel
formation. Previously, we found that VEGF concentration
in the coronary sinus (CS) and severity of coronary artery
stenosis are positively correlated with collateral formation
[7]. Patients with total coronary artery occlusions have
more developed collateral channels than those with partial
occlusions.
Based on these findings, we hypothesized that patients
with total coronary artery occlusion have higher local growth
factor concentrations, and these concentrations may play a
part in angiogenesis. The purpose of this study was to
© 2005 Elsevier. All rights reserved.
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compare VEGF and TGF-`1 concentrations in the CS and
right atrium (RA) in coronary artery disease patients with
total occlusion and with partial occlusion.
MATERIALS AND METHODS
Patient enrollment
The research protocol was approved by our institution’s
ethics committee. From March 2000 to October 2001, we
evaluated patients scheduled for diagnostic coronary artery
angiography at Kaohsiung Medical University Hospital for
possible recruitment into the study. Indications for coronary
artery angiography included known or suspected coronary
artery disease. Suspected coronary artery disease was
defined as ischemia documented by treadmill test or
radionuclide myocardial perfusion scan.
Data collection
Baseline data for each patient included name, sex, age,
history of diabetes, hypertension, hypercholesterolemia
and cigarette smoking.
Coronary artery angiography films were reviewed by
an experienced cardiologist. Recorded data included the
number of diseased vessels, the affected vessels, and the
presence or absence of total coronary artery occlusion.
Significantly diseased vessels were defined as a reduction
in lumen diameter of at least 50%. The reviewer was blind
to growth factor data when interpreting the coronary
anatomy. We used the collateral scoring system developed
by Cohen and Rentrop [8].
Blood collection
Because heparin would change growth factor concentrations,
blood samples were collected before intravenous
heparinization for diagnostic coronary artery angiography [9].
We used a 6F Goodale-Lubin catheter under fluoroscopic
guidance to collect blood samples from the CS (20 mL).
After the catheter was withdrawn from the CS, it was used
to collect blood samples from the RA (20 mL). Blood was
collected into a sterile tube containing ethylenediamine
tetraacetic acid as anticoagulant, and quickly put on ice.
Tubes were centrifuged at 3,000 rpm for 10 minutes at room
temperature, and 500 +L of plasma was removed from each
tube and frozen at –80$C until analysis.
Measurement of VEGF and TGF-`1 concentrations
Plasma VEGF and TGF-`1 concentrations were measured
using a  quanti tat ive  sandwich enzyme-l inked
immunosorbent assay kit (ELIZA; R&D Systems Europe
Ltd, UK, and Biosource, Europe SA).
Statistical analysis
Data are reported as mean (  standard error of the mean.
The Chi-squared test and Wilcoxon rank-sum test were
used to compare non-parametric data. The t test was used
for analysis between continuous variables. Statistical
analysis was performed using SPSS statistical software,
version 10 (SPSS Inc, Chicago, IL, USA). A p value of less
than 0.05 was considered statistically significant.
RESULTS
Patient enrollment and study group
characterization
Fifty-one consecutive patients were enrolled in this study.
One patient was excluded due to difficulties in
catheterization of the CS, and three were excluded due to
inadequate blood sampling. Of the remaining 47 patients,
32 had at least one major epicardial coronary stenosis.
Seven patients had at least one totally occluded major
epicardial vessel.
Table 1 shows the baseline characteristics of the two
groups and the number of diseased epicardial coronary
vessels involved. Of the 32 patients, five (16%) had one
diseased vessel, six (19%) had two diseased vessels,
and 21 (65%) had three diseased vessels. There was no
significant difference in any variables between patients
with total occlusions and those with non-total occlusions.
Compared with patients with partial occlusion, those
with total occlusion had greater coronary stenosis severity
(100 vs 87.0% (  2.1%; p = 0.003) and collateral grade
(2.1 (  0.3 vs 0.8 (  0.2; p = 0.006).
VEGF and TGF-`1 concentrations
The 32 study patients had higher VEGF concentrations in
the CS than in the RA (31.5 (  2.7 vs 27.1 (  1.8 pg/mL;
p = 0.005). However, no significant difference was found in
TGF-`1 concentrations between the CS and RA (202 ( 34.2
vs 250 ( 37.8 pg/mL; p = 0.240).
CS VEGF concentrations were higher in patients with
total coronary artery occlusions than those with non-total
occlusions (38.9 (  8.0 vs 29.5 ( 2.6 pg/mL; p = 0.037). The
difference in RA VEGF concentrations in these two groups
was not significant (Table 2). TGF-`1 concentrations in the
CS and RA were not significantly different between patients
with total and non-total occlusion (Table 2).
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DISCUSSION
This study had two noteworthy findings. Patients with
significant coronary artery disease had higher VEGF
concentrations in the CS than in the RA, and patients with
total occlusions had higher CS VEGF concentrations and
collateral grade than those with non-total occlusions.
The severity of coronary artery obstruction plays an
important role in the development of coronary collateral
channels. Coronary collaterals do not develop until there is
a coronary stenosis with a narrowing in diameter of 70% or
more. Beyond this threshold value, the growth of collateral
channels is directly related to stenosis severity [10]. The
transformation of preexisting collaterals into mature
collaterals is called arteriogenesis [1,11]. VEGF may play an
important role in this process in vivo. Some studies have
demonstrated that administering various angiogenic growth
factors, including VEGF, can augment revascularization of
the myocardium [12,13].
Schultz et al found that the ability to respond to
progressive coronary artery stenosis by growing coronary
artery collaterals is strongly associated with the ability to
induce VEGF in response to hypoxia [14]. The CS is located
in the downstream ischemic myocardium, and its growth
factor concentrations may more accurately reflect the amount
of growth factors in the ischemic myocardium than upstream
in the coronary artery. Recently, El-Gendi et al reported that
basal VEGF concentrations were significantly higher in the
CS samples of patients with occlusions than in those with
stenosis [15], which was similar to our findings. However,
they failed to show a local increase in basic fibroblast
growth factor, which we did not measure. Although the
differences we found were insignificant, this is the first
study to measure local CS TGF-`1 concentrations and assess
their role in arteriogenesis in diseased coronary circulation
in vivo. Our data showed that VEGF concentrations in the
CS were higher than those in the RA, where blood is mixed
with venous blood from the superior and inferior vena
Table 1. Patient characteristics
Covariate Occlusion (n = 7) Stenosis (n = 25) p
Age (yrs) 64 ( 12 60 ( 11 NS
Male (%) 6 (86) 19 (76) NS
Female (%) 1 (1) 6 (2) NS
Diabetes (%) 1 (14) 12 (48) NS
Hypertension (%) 5 (71) 13 (52) NS
Hypercholesterolemia (%) 6 (86) 14 (56) NS
Smoking (%) 4 (57) 13 (52) NS
No. of diseased vessels 2.6 ( 0.5 2.5 ( 0.8 NS
Diseased vessel
LAD (%) 0 5 (20) NS
LAD and LCX (%) 1 (14) 0
LAD and RCA (%) 1 (14) 1 (4)
LCX and RCA (%) 1 (14) 2 (8)
Three-vessel disease (%) 4 (57) 17 (68)
Stenosis (%) 100 87.0 ( 2.1 0.003
Collateral grade 2.1 ( 0.3 0.8 ( 0.2 0.006
NS = not significant; LAD = left anterior descending artery; LCX = left circumflex artery; RCA = right coronary artery.
Table 2. Vascular endothelial growth factor (VEGF) and transforming growth factor `  (TGF-`1) concentrations in the coronary sinus
(CS) and right atrium (RA) between patients with total occlusion and non-total occlusion (stenosis)
Occlusion (pg/mL) Stenosis (pg/mL) p
VEGF in CS 38.9 ( 8.0 29.5 ( 2.6 0.037
VEGF in RA 31.7 ( 2.9 25.8 ( 2.0 0.810
TGF-`1 in CS 188.6 ( 37.6 250.3 ( 82.8 0.460
TGF-`1 in RA 317.3 ( 111.3 230.9 ( 37.8 0.340
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cava. This finding further emphasized the local paracrine
role of VEGF in angiogenesis.
In acute myocardial infarction, the totally occluded
vessel causes hypoxia, which induces the release of VEGF,
and which peaks between the 7th and 14th day after the
infarction [16–18]. If patients receive reperfusion therapy,
their elevated VEGF concentrations rapidly return to nearly
pre-infarction concentrations [19]. Thus, the elevation of
VEGF in the 1–2 weeks after acute myocardial infarction
may be related to collateral channel formation [20].
Interestingly, Kranz et al have reported that such elevated
VEGF during acute myocardial infarction originates from
platelets, instead of the infarct myocardium [21]. There is
little research into local concentrations of growth factors in
non-infarction subjects. In the current era of therapeutic
angiogenesis, the more detail we have about the local
concentrations of growth factors, the more we will be able
to decide on the amount of growth factor needed to
adequately enhance angiogenesis.
TGF-`1 levels have also been correlated with
angiogenesis [22], and are thought to spur the differentiation
and maturation of pericytes and smooth muscle cells [23].
TGF-`1 signaling may regulate VEGF expression in cardiac
myocytes [5]. Low TGF-`1 concentration has been correlated
with arteriogenesis [24]. Recently, Werner et al reported
that higher TGF-`1 concentrations were observed in
collaterals distal to the chronic total occlusion but did not
have a close relationship to the duration of occlusion [25].
However, we did not find any local difference in TGF-`1
concentrations in either the CS or RA. Therefore, further
investigation is needed to determine whether TGF-`1 plays
a role in angiogenesis.
Some small and promising studies reporting the use of
VEGF to enhance angiogenesis have evaluated VEGF
delivery to the ischemic myocardium via different routes,
including the intramyocardial [13,26–28], intracoronary
[29,30], and intravascular routes [3]. Plasmids [13,26,28]
and adenoviruses [27] have been used as vectors to bring
VEGF DNA to the target. Most of these studies have reported
a good tolerance of vectors and positive results. Recently,
however, the first published randomized, controlled trial of
VEGF for therapeutic angiogenesis, the VIVA trial [3],
showed that significant improvement in angina and
favorable trends in angina frequency were found in only
high-dose groups. Furthermore, the optimal VEGF dose
and duration of administration needed to adequately
enhance angiogenesis are questionable, with one reason
being a lack of local growth factor concentration data from
living men with significant coronary artery disease.
By understanding local concentration, we can adjust growth
factor dosage and monitor whether such delivery can
provide adequate local concentration.
This preliminary report discusses local VEGF
concentration in patients with significant coronary artery
disease. Larger trials will be needed to measure VEGF
concentrations in patients with coronary artery disease at
different levels of severity. More studies are needed on the
use of alternative growth factors and optimal concentrations
to enhance the benefits derived from using angiogenic
growth factors to treat severe myocardial ischemia patients
who are not good candidates for standard revascularization.
Study limitations
Limitations of this study include the small number of
patients; a larger number of patients might add important
information regarding the role of TGF-`1 in angiogenesis.
The present study shows that patients with total coronary
artery occlusion have higher CS VEGF concentrations than
those with non-total occlusion, indicating that VEGF may
play a part in angiogenesis.
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